Regorafenib
C21H15ClF4N4O3·H2O
500.83
2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, monohydrate;
4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
[1019206-88-2] Anhydrous C21H15ClF4N4O3 482.82
[755037-03-7]
2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, monohydrate;
4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
[1019206-88-2] Anhydrous C21H15ClF4N4O3 482.82
[755037-03-7]
DEFINITION
Regorafenib contains NLT 97.5% and NMT 101.5% of regorafenib (C21H15ClF4N4O3), calculated on the anhydrous and solvent-free basis.
USP REFERENCE STANDARDS FOR PURCHASE
USP Regorafenib RSUSP Regorafenib Related Compound A RS
USP Sorafenib Tosylate RS